Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13774603 | 0.83 | POLB (0.46) | CD274LMNAEPHX2POLBALDH1A1 | |
| SCHEMBL4158059 | 0.83 | CASR (0.37) | CASRLMNAALDH1A1 | |
| SCHEMBL4149965 | 0.80 | ACKR3 (0.38) | EPHX2ALDH1A1TACR1 | |
| SCHEMBL4160290 | 0.80 | MAPK1 (0.45) | CASRLMNAALDH1A1TACR1TACR3 | |
| SCHEMBL4150001 | 0.79 | MAPK1 (0.35) | LMNAEPHX2ALDH1A1 | |
| SCHEMBL4163032 | 0.79 | PDK2 (0.33) | CASREPHX2 | |
| SCHEMBL13774526 | 0.78 | MCHR1 (0.37) | HSD17B10LMNAEPHX2ALDH1A1BACE1 | |
| SCHEMBL4637471 | 0.78 | LMNA (0.48) | CASRCD274HSD17B10LMNAEPHX2 | |
| SCHEMBL4150851 | 0.78 | PTPRZ1 (0.36) | LMNAEPHX2ALDH1A1 | |
| SCHEMBL4145149 | 0.76 | TACR2 (0.36) | EPHX2TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1937629-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007046513-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007046513-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | BTK, BRIX1, NFXL1 | CASR 1722/4885CD274 4635/4885HSD17B10 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.